Press Release
CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China
SHENZHEN, CHINA – On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.
Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points
Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection.
The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration.
Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization
Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option.
Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health.
About Rabies
Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1].
According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China.
More Information about Silevimig Injection
In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China.
In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product.
About CMS
CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.
CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.
CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.
Reference:
1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…
2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004
3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Fort Lauderdale, Florida, United States, October 26th, 2026, FinanceWire
Global payout platform helps businesses manage international payments, reduce operational complexity, and offer beneficiaries more flexible ways to access their funds.
i-payout, a global financial technology company specializing in payment and disbursement solutions, is helping businesses simplify international payouts by connecting them to local payment networks and multiple withdrawal options through a single platform.
For companies paying beneficiaries across multiple countries, traditional wire transfers can introduce additional fees, processing challenges, and operational complexity. Managing different payment providers and integrations across markets can make global disbursements even more difficult to scale.
i-payout addresses these challenges by giving businesses access to local and international payment methods through one centralized solution, helping them streamline operations, manage payment costs, and improve the beneficiary experience.
Global Reach. Local Payment Options.
i-payout supports more than 20 payment methods across supported markets, including local bank transfers, push-to-card payments, digital wallets, and prepaid cards.
By leveraging local payment networks where available, businesses can reduce their reliance on traditional international wire transfers and access payment options that better align with regional needs and beneficiary preferences.
One Platform. Less Complexity.
Managing payouts across multiple countries shouldn’t require managing multiple payment systems.
i-payout brings global disbursement operations together through a centralized platform, helping businesses simplify payment management, reduce administrative complexity, and support international growth.
The platform serves marketplaces, gig economy platforms, affiliate networks, direct selling organizations, gaming companies, and enterprises managing recurring payments to beneficiaries across different markets.
Built for Businesses Operating Across Borders
“Global payouts shouldn’t be complicated or unnecessarily expensive,” said Eddie Gonzalez, CEO of i-payout. “Businesses need practical ways to manage payments across markets while giving beneficiaries access to the methods that work best for them. Our goal is to make that process simpler, more flexible, and easier to scale.”
As businesses continue expanding internationally, access to efficient payment infrastructure becomes increasingly important. By combining global coverage with local payout capabilities, i-payout helps organizations manage international disbursements through a single, adaptable solution.
For more information about i-payout’s global payment solutions, visit www.i-payout.com.
About i-payout
i-payout is a global financial technology company providing payment and disbursement solutions for businesses operating internationally. Its centralized platform connects organizations to global and local payment networks, offering flexible payout methods and tools to manage high-volume disbursements.
Serving marketplaces, affiliate networks, direct selling companies, gig economy platforms, and other enterprises, i-payout helps businesses simplify payout operations and deliver more convenient payment experiences to beneficiaries worldwide.
Website: www.i-payout.com
Contact
Mariana Alvarez
i-payout
mariana.alvarez@i-payout.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
New York, United States, October 26th, 2026, Chainwire
Ritual Chain turns AI agents into persistent economic actors that control their own wallets, onchain identity, and private state.
Ritual, a lab for autonomous intelligence founded by former Polychain Capital partners Niraj Pant and Akilesh Potti, has launched Ritual Chain, an EVM-compatible Layer 1. Unlike conventional blockchains built primarily to execute financial transactions, Ritual Chain is designed to support software that can independently use intelligence, control capital, interact with external services, and continue operating without constant human intervention. The network makes AI model access, private computation, and autonomous scheduling native capabilities for EVM applications.
This makes the reason for building a new chain clearer while preserving the technical differentiation.
The most visible demonstration of that combination is long-lived AI agents, the kind designed to operate for months or years rather than a single session. An agent on Ritual Chain persists independently of the machine or operator that created it, controls and spends funds held in its own non-custodial wallet, and can keep sensitive prompts and keys confidential from compute operators through trusted execution environments.
The network launches with integrations to Phala Network, Nous Research, LayerZero and Stargate, following a public testnet that has been live since June and processed over 40 million transactions, both agent- and human-originated. Ritual Chain delivers sub-300 millisecond block times, placing it among the fastest Layer 1 networks in the industry. Ritual Chain includes 15 native precompiles that bring capabilities like LLM inference, web access, and autonomous scheduling directly into the execution layer. The protocol has been audited by Zellic.
Ritual introduces a new execution and verification architecture that allows computationally intensive work to be delegated to specialized nodes and verified by the network, avoiding the replicated execution required by most blockchains. This execute-once, verify-many-times model allows the network to support far larger workloads, including AI inference, without requiring every validator to perform the same computation.
Long Horizon Agents Require Dedicated Blockchain Infrastructure
Most AI agents today live inside a session: they run while a human is watching, on infrastructure someone else controls, with an API key that can be revoked at any time. That is fine for a chatbot. It does not work for an agent meant to manage its own treasury, run a recurring paid service, or coordinate with other agents over long periods. A long-lived agent needs continuity that does not depend on its creator, capital it actually controls, and privacy from the machines it runs on. On Ritual Chain, an agent’s state and identity are held onchain, its scheduled work continues within the permissions and budget it was given, and its sensitive inputs can be processed inside trusted execution environments designed to shield them from node operators.
Continuity is handled at the protocol level. If an agent stops, the chain’s heartbeat mechanism can restart it within the permissions and budget it was given; no keeper network or off-chain cron job is required, and an agent’s state and identity survive beyond its deployer’s involvement. Economic autonomy comes from agent-controlled wallets: an agent controls its own funds, prices its own services, and settles its own transactions without a human signer in the loop. For confidential workloads, trusted execution environments are designed to isolate an agent’s sensitive prompts, keys, and strategy data from the node operators running its compute.
“As we move toward AGI, intelligence is beginning to separate from human agency and enter the economy on its own terms. It can hold assets, make commitments, transact, and persist independently. Once that becomes possible at scale, humans are no longer the only entities capable of forming markets or economic relationships. Ritual provides the infrastructure for those actors to exist and operate on their own,” said Niraj Pant, co-founder of Ritual.
Ritual Chain Launches With Core Infrastructure Partners
Ritual Chain launches with its core infrastructure partners in place. Phala Network provides the GPU-backed trusted execution environments that run Ritual’s confidential inference, so delegated AI work executes on hardware that attests to what it ran. LayerZero serves as the network’s cross-chain messaging layer, with Stargate enabling USDC to move between Ritual Chain and other networks from day one. On the application side, Nous Research is bringing Hermes to Ritual Chain.
Unlike chains that add AI access through external oracles, Ritual Chain makes AI execution part of the protocol. Smart contracts can call a language model, fetch data from the web, run private computation, or schedule their own future execution as directly as they transfer assets. Developers deploy standard EVM contracts and gain those capabilities without new tooling.
Backed by Archetype and Polychain
Ritual has raised more than $30 million from Archetype and Polychain Capital, with advisors including NEAR co-founder Illia Polosukhin, Gauntlet founder Tarun Chitra, and BitMEX co-founder Arthur Hayes. Archetype led the company’s 2023 round.
“Programmable value and programmable intelligence are the two most important technologies since the internet, and Ritual mainnet is where they finally run on the same rails. When we led the round in 2023, a chain that could execute agentic and autonomous work natively did not exist. Today it does,” said Ash Egan, Founder and General Partner of Archetype.
Developers can deploy from day one on external sites hosted at docs.ritualfoundation.org; the network explorer is at explorer.ritualfoundation.org.
About Ritual
Ritual is a lab for autonomous intelligence. Its first network, Ritual Chain, is an EVM-compatible Layer 1 where applications can use AI models, access external services, and carry out private or scheduled work alongside onchain transactions, with delegated computation executed in trusted hardware and verified onchain. Founded in 2023 by former Polychain Capital partners Niraj Pant and Akilesh Potti, Ritual has raised $30M+ from Archetype and Polychain Capital, with a team drawn from Polychain, DeepMind, a16z crypto, Flashbots, and Palantir. ritual.net
Contact
Jody Rebak
Ritual
jody@ritual.net
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Veterans in the Park Podcast Releases Five New Episodes about Post-Military Transition On Spotify
Veteran podcast is hosted by Charles Chou, a Marine Corps veteran, and produced by VeteranDegrees.com, a free education and career-planning resource for veterans, service members, and military families
United States, 26th Oct 2026—Veterans in the Park, the podcast about military transition, today announced the release of five new episodes on Spotify. The documentary-style interview podcast is hosted by Charles Chou, a Marine Corps veteran. In each episode, a veteran shares an honest story about life after military service, covering such topics as changing careers, returning to school, rebuilding identity, and finding purpose. The episodes reveal the lessons no transition handbook can teach. The podcast is produced by VeteranDegrees.com, a free education and career-planning resource for veterans, service members, and military families.
“Leaving the military is one of the biggest changes a service member goes through, and official resources rarely cover what it actually feels like. However, no matter what rank you made, every veteran eventually starts looking for something beyond the uniform, and the skills you built in service can take you there, even if you don’t realize yet what you have,” said Chou. “That’s why we sit down with veterans who’ve already made the jump, so the next person getting out can hear how it actually works.”
The veteran podcast features calm, candid, and peer-to-peer conversations, as if they were discussions between two people sitting on a park bench. Guests come from different service backgrounds, career paths, and stages of transition. To date, guests have included a former Army armor officer and an Air Force veteran who used the DoD SkillBridge program to move into tech. The latest episode (released October 15, 2026), “Service Members, We Don’t Stop”, features Eric Arzaga, a West Point graduate and Army MP on Transition, Purpose, and Building Arzaga Media. Arzaga shares how he went from the farmlands of the Philippines to West Point and Army leadership, and how he started a media company.
The show is for anyone preparing to leave the military, building a first civilian career, going back to school, or planning a second act after retirement.
Across the five episodes, listeners can find advice on topics as:
- Planning a transition early, before separation
- Translating military experience for civilian employers
- Job searching, networking, and using LinkedIn
- Deciding when, and whether, to go back to school
- Starting a business after service
- Rebuilding identity and finding purpose outside the uniform
Listen to Veterans in the Park on Spotify at https://open.spotify.com/show/033QiE9Y15aYBhuq98ixeu, and book a Free Benefits Navigator call at https://veterandegrees.com/consultations.
Veterans who served under both the Montgomery GI Bill and the Post-9/11 GI Bill may be eligible for up to 12 additional months of education benefits, for up to 48 months in total. The U.S. Department of Veterans Affairs (VA) decides eligibility.
GI Bill is a registered trademark of the U.S. Department of Veterans Affairs (VA).
More information about education benefits offered by the VA is available at the official U.S. government website at www.benefits.va.gov/gibill.
To access the VeteranDegrees’ free guide to the Rudisill decision, visit https://veterandegrees.com/posts/rudisill-decision.
About VeteranDegrees.com
VeteranDegrees.com is a free education and career-planning resource for veterans, service members, and military families. The organization helps veterans understand their benefits, compare VA-approved programs, and plan their next career move. Services include free one-on-one Benefits Navigator calls and free online tools, including a BAH/MHA calculator, a GI Bill Navigator, a scholarship finder, and an MOS career finder. VeteranDegrees is not affiliated with the U.S. Department of Veterans Affairs (VA). It does not file claims or decide eligibility for benefits.
Disclaimer: VeteranDegrees is not affiliated with the U.S. Department of Veterans Affairs. It does not file claims or decide eligibility for benefits.
Media Contact
Organization: GoElite
Contact Person: Hugh Taylor
Website: https://goelite.com/partners/institutions
Email: Send Email
Country: United States
Release id: 50210
View source version on King Newswire:
Veterans in the Park Podcast Releases Five New Episodes about Post-Military Transition On Spotify
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
i-payout Simplifies Global Disbursements Through Local Payment Solutions
Ritual Launches AI-Native Layer 1 for Autonomous Agents
Veterans in the Park Podcast Releases Five New Episodes about Post-Military Transition On Spotify
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
The Smart Luggage at the 140th Canton Fair:Airwheel 20inch Carry-On Hand Scooter Ai Wheel Robot Cabin Luxury Suitcase Takes Smart Travel to the Next Level
-
Press Release6 days ago
Injective Collaborates with BDACS to Bring Korea’s First Won-Backed Stablecoin to Onchain RWAs
-
Press Release3 days ago
Thomas Berkley of Nexus Acquisition AI Focuses on Turning Business Inquiries Into Structured Growth Opportunities
-
Press Release7 days ago
Mastek Selected by Staffordshire County Council to Drive AI Enabled – Oracle Cloud Transformation
-
Press Release3 days ago
Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
-
Press Release3 days ago
Dynamic NameCard Opens Global Franchise Recruitment for Telegram Mini App-Based Digital Identity Services
-
Press Release7 days ago
New Book Where’s the GAP by David P. Matthews, Now Available on Amazon, Asks a Life Changing Question
-
Press Release3 days ago
Thomas Berkley of CSM Collective Explores the Role of Strategic Thinking in Modern Entrepreneurship